Ep.119 – New Rules for Old Infections: What the DOTS Trial Tells Us

Episode Notes Join DASON Clinical Pharmacist Liaison Jeannette Bouchard as she speaks with Dr. Nick Turner, lead author of the DOTS randomized clinical trial, about the potential of dalbavancin as a simplified treatment for Staphylococcus aureus bacteremia. They discuss the trial’s findings, its implications for clinical practice, and whether two doses can truly replace weeks of IV antibiotics. The materials reviewed in this episode can be found here: https://dason.medicine.duke.edu/blog/new-rules-old-infections-what-dots-trial-tells-us For more information about DASON, please visit: https://dason.medicine.duke.edu

There are no comments yet.

Please log in to write the first comment.